10-Q: Myomo Inc. Reports Strong Revenue Growth in Q3 2024, Nears Cash Flow Breakeven

Myomo Inc. saw a significant increase in product revenue and gross profit in the third quarter of 2024, driven by Medicare reimbursements, and anticipates achieving operating cash flow breakeven by the end of the year.

Summary

• Myomo Inc. reported a substantial increase in product revenue, reaching $9.2 million for the three months ended September 30, 2024, compared to $5.0 million for the same period in 2023.
• The company's gross profit also saw a significant rise, increasing to $6.9 million in Q3 2024 from $3.5 million in Q3 2023.
• This growth was primarily driven by higher sales volumes and average selling prices due to Medicare Part B reimbursements.
• For the nine months ended September 30, 2024, product revenue totaled $20.5 million, up from $12.7 million in the same period of 2023.
• The company's net loss for the quarter was $0.97 million, an improvement from the $2.0 million loss in Q3 2023.
• Myomo believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024, based on current trends and if supply chain and payment expectations are met.
• The company has a revolving line of credit of up to $4.0 million, with approximately $0.9 million available as of September 30, 2024.
• Myomo completed a registered direct equity offering in January 2024, generating net proceeds of approximately $5.4 million.

Sentiment

Score: 8

Explanation: The document shows strong positive trends in revenue and gross profit, with a clear path to potential cash flow breakeven. While there are risks, the overall sentiment is positive due to the company's growth trajectory and financial improvements.

Positives

• The company experienced significant revenue growth, driven by increased sales and higher average selling prices.
• Gross profit and gross margin improved substantially, indicating better cost management and pricing strategies.
• The company is on track to potentially achieve operating cash flow breakeven in the near future.
• Myomo has secured additional funding through a line of credit and equity offerings, strengthening its financial position.
• Medicare Part B reimbursements are a significant driver of revenue growth.

Negatives

• The company continues to incur net losses, although the loss has decreased compared to the previous year.
• Operating expenses have increased, particularly in research and development, selling, clinical, and marketing, and general and administrative areas.
• The company's direct billing revenues are concentrated with a small number of payers, including CMS, which poses a risk if reimbursement policies change.
• Myomo relies on a single third-party manufacturer for key subassemblies, creating a potential supply chain risk.

Risks

• The company's ability to achieve cash flow breakeven is dependent on several factors, including supply chain stability, payment collection, and continued revenue growth.
• Adverse changes in Medicare reimbursement policies could significantly impact the company's revenue.
• The company relies on a single third-party manufacturer for key subassemblies, which could disrupt production if issues arise.
• The market for myoelectric braces is new, and the rate of adoption is uncertain.
• The company is subject to extensive governmental regulations, and failure to comply could lead to product recalls or withdrawal from the market.
• Cyber-attacks or security breaches could disrupt operations and compromise sensitive data.
• The company's success depends on its ability to protect its intellectual property.
• The market price of the company's common stock has been and may continue to be volatile.

Future Outlook

Myomo believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024, based on current trends and if supply chain and payment expectations are met. The company plans to grow revenues by serving an increasing number of Medicare patients and training O&P providers in the United States.

Management Comments

• Management's operating plans are primarily focused on growing revenues in its direct billing channel by serving an increasing number of Medicare patients and training O&P providers in the United States.
• Based on the final fees published by the Centers for Medicare and Medicaid Services (CMS) for the Companys products, which became effective on April 1, 2024, if its supply chain is able to meet its volume requirements without disruption, the Company is able to compensate for additional advertising spending in the second half of 2024 above its original plan, expected payments are received and there is no increase in days sales outstanding in the fourth quarter, the Company believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024.

Industry Context

The announcement reflects a positive trend in the medical robotics industry, particularly in the area of wearable orthotics. The company's focus on direct billing and Medicare reimbursements aligns with the industry's shift towards value-based healthcare. The company's success in obtaining Medicare coverage and achieving higher average selling prices is a positive sign for the adoption of myoelectric orthotics.

Comparison to Industry Standards

• Myomo's revenue growth of 83% in Q3 2024 is significantly higher than the average growth rate for medical device companies, which typically ranges from 5% to 15% annually.
• The company's gross margin of 75.4% is also above the industry average for medical device manufacturers, which is typically between 50% and 70%.
• Compared to companies like Ekso Bionics and ReWalk Robotics, which also develop wearable robotic devices, Myomo's focus on upper limb orthotics and direct billing model is a differentiating factor.
• While Ekso Bionics and ReWalk Robotics have faced challenges in achieving profitability, Myomo's path to cash flow breakeven in Q4 2024 is a positive sign.
• The company's reliance on a single third-party manufacturer is a common practice in the medical device industry, but it also presents a risk that needs to be managed effectively.
• Myomo's success in obtaining Medicare coverage and achieving higher average selling prices is a positive sign for the adoption of myoelectric orthotics, which is a key factor for long-term growth.

Legal Proceedings

• During the fourth quarter of 2023, the Company settled an age discrimination claim by a former employee.
• The settlement was paid and all insurance proceeds were received during the three months ended March 31, 2024.
• There is no other material litigation against the Company at this time.

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and potential cash flow breakeven.
• Employees may see increased job security and opportunities for growth as the company expands.
• Customers will have greater access to the MyoPro device through increased Medicare coverage and O&P provider training.
• Suppliers will benefit from increased demand for components and subassemblies.
• Creditors will have increased confidence in the company's ability to repay its debts.

Next Steps

• The company plans to continue growing revenues in its direct billing channel by serving an increasing number of Medicare patients.
• Myomo will focus on training O&P providers in the United States to provide the MyoPro to their patients.
• The company will continue to monitor its supply chain to ensure it can meet volume requirements without disruption.
• Myomo will continue to monitor and manage its advertising spending to maximize its impact on revenue growth.

Key Dates

Keywords

MyoPro, myoelectric orthotics, Medicare, reimbursement, medical devices, revenue growth, gross profit, cash flow breakeven, healthcare, medical robotics